Spectranetics To Study Laser-Assisted In-Stent Restenosis Therapy
This article was originally published in The Gray Sheet
Executive Summary
Spectranetics is preparing to evaluate a laser-assisted treatment for in-stent restenosis that could offer an alternative to coronary artery bypass surgery.
You may also be interested in...
Spectranetics Unfazed By Study On Laser Use For In-Stent Restenosis
Spectranetics is confident that clinical trials for the firm's CVX-300 excimer laser will demonstrate the device to be effective in treating in-stent restenosis despite unfavorable results reported in a recently completed independent study.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.